Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MF59 adjuvanted H5N1 influenza vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms | EXPERIMENTAL | - |
| MF59 adjuvant H5N1 influenza vaccine 15 micrograms | EXPERIMENTAL | - |
| non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MF59 adjuvanted H5N1 influenza vaccine | BIOLOGICAL | * MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1 * non-adjuvanted influenza vaccine containing 15 ug of H5N1 |
Inclusion Criteria: * Male and female volunteers 18-60 years of age Exclusion Criteria: * Any auto-immune disease or other serious acute, chronic or progressive disease * Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other compo...
MF59 adjuvanted H5N1 influenza vaccine is an investigational vaccine being developed for influenza. It is designed to generate an immune response against the H5N1 influenza virus strain. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
MF59 adjuvanted H5N1 influenza vaccine is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in adults.
MF59 adjuvanted H5N1 influenza vaccine is in Phase 2 clinical development. It is an investigational vaccine, meaning it has not yet been approved for commercial use. The Phase 2 trial has been completed, and the vaccine remains under evaluation.
MF59 adjuvanted H5N1 influenza vaccine has one completed clinical trial, NCT00382187, titled 'Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults.' This Phase 2 trial enrolled 40 healthy adult volunteers in Italy and evaluated the vaccine's safety and immune response.
MF59 adjuvanted H5N1 influenza vaccine is a specific formulation that includes the MF59 adjuvant to enhance immune response. It is designed for H5N1 influenza, a strain with pandemic potential. The vaccine is distinct from seasonal flu vaccines and is being studied for its ability to protect against this particular strain.